Watch: A Safe, Accessible Treatment for ME/CFS? The IVO-21 Study
Could IVO-21 Lead to a New ME/CFS Mitochondrial Treatment? In May 2026, Solve selected Dr.
September 12, 2026
Could IVO-21 Lead to a New ME/CFS Mitochondrial Treatment? In May 2026, Solve selected Dr.
August is Severe ME/CFS Awareness Month–a time to reflect on the toll this disease takes
This quarter’s summaries highlight several studies examining the biological mechanisms of ME/CFS and Long Covid,
Dr. Avik Roy is the chief scientific officer at the Simmaron Research Institute, a nonprofit
Solve M.E. today announced Renegade Research as the latest recipient of our ME/CFS Catalyst Award,
Our CEO, Emily Taylor, is featured in LA Weekly for her leadership in shaping the
In recognition of World ME Day, Solve M.E. announced today new funding for two award-winning
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst
When an organization, like a government agency, company, or nonprofit, considers a big change or
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the
In our “What’s New in ME/CFS?” series, we spotlight researchers transforming what we can do
Solve M.E. is proud to support two pioneering studies through our latest round of ME/CFS
Move science forward with a gift to Solve today.